Quantcast

Latest MDV3100 Stories

2010-04-14 17:31:00

SAN FRANCISCO and TOKYO, April 14 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. today announced publication of positive results from their previously reported Phase 1-2 trial of the novel triple-acting oral androgen receptor antagonist MDV3100 in men with progressive, metastatic castration-resistant prostate cancer in the April 15 online version of The Lancet. According to the published results, MDV3100 demonstrated anti-tumor activity in patients with...

2009-10-23 07:00:00

SAN FRANCISCO, Oct. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the appointment of Hank Mansbach, M.D., as vice president of medical affairs. Dr. Mansbach will lead Medivation's medical affairs activities for dimebon (latrepirdine*), the company's Phase 3 candidate for the treatment of Alzheimer's and Huntington diseases, and MDV3100, which is in Phase 3 clinical development for the treatment of advanced prostate cancer. "Hank brings a vast array of...

2009-09-23 07:00:00

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced treatment of the first patient in a Phase 3 clinical trial of the investigational drug MDV3100 in advanced prostate cancer. Known as AFFIRM, the trial will evaluate the novel androgen receptor antagonist MDV3100 in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. "Late stage prostate cancer remains an obvious and large unmet...

2009-06-02 08:23:00

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced the presentation of new clinical results from a Phase 1-2 trial evaluating MDV3100, a next-generation androgen receptor antagonist, in castration-resistant prostate cancer (CRPC) patients. The new findings, which include data from all 140 enrolled patients,...

2009-05-21 07:00:00

SAN FRANCISCO, May 21 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla. Oral Abstract Session: Genitourinary (Prostate) Cancer Abstract Title:...

2009-05-11 15:01:00

- Conference Call Today at 4:30 p.m. Eastern Time - SAN FRANCISCO, May 11 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the first quarter ended March 31, 2009. "We continue to make significant progress with both of our product candidates -- Dimebon in patients with Alzheimer's and Huntington's diseases and MDV3100 in patients with prostate cancer. Having received written permission from the FDA to initiate a...

2009-04-23 07:00:00

SAN FRANCISCO, April 23 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced several presentations at upcoming medical conferences that will feature its investigational drugs MDV3100 and Dimebon. MDV3100 2009 American Urological Association (AUA) Annual Meeting, April 25-30, Chicago Podium presentation featuring MDV3100 on Sunday, April 26, at 4:00 p.m. Central Time (POD17. Prostate Cancer: Advanced Dimebon 61st American Academy of Neurology (AAN) Annual Meeting,...

2009-04-10 15:36:38

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal form of the disease, known as castration-resistant prostate cancer, or CRPC. Also referred to as hormone-refractory prostate cancer, CRPC is...

2009-04-09 07:39:41

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels "“ a marker for tumor growth "“ in men with advanced prostate cancer for whom traditional treatment options have failed. The study, led by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC), is published today in Science Express, the online version of the journal Science.Most men with metastatic prostate cancer eventually build up resistance to the drugs that lower or...

2009-04-09 00:36:02

An experimental drug lowers prostate specific antigen levels -- a marker for tumor growth -- in men with advanced prostate cancer, U.S. researchers say. Researchers at Memorial Sloan-Kettering Cancer Center in New York said most men with metastatic prostate cancer eventually build up resistance to the drugs that lower or block male hormones and develop a more aggressive form of the illness called castration-resistant prostate cancer, or hormone-refractory disease. The study, published in...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.